Automate Your Wheel Strategy on UNCY
With Tiblio's Option Bot, you can configure your own wheel strategy including UNCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol UNCY
- Rev/Share 0.0462
- Book/Share 1.3355
- PB 3.2161
- Debt/Equity 0.029
- CurrentRatio 2.1765
- ROIC -1.8021
- MktCap 54839419.0
- FreeCF/Share -2.698
- PFCF -1.6522
- PE -1.6775
- Debt/Assets 0.0159
- DivYield 0
- ROE -2.0005
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | UNCY | Guggenheim | -- | Buy | -- | $6 | April 21, 2025 |
News
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit.
Read More
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCY
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options
Read More
Unicycive Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – UNCY
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit.
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCY
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and …
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the …
Read More
UNCY Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Unicycive Therapeutics, Inc. Class Action
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCY
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and …
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options
Read More
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and …
Read More
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025.
Read More
Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - October 14, 2025 Deadline to Join – Contact The Gross Law Firm
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive or the “Company”) securities between March 29, 2024 and June 7, 2025, inclusive (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Claims: Investors allege violations of the Securities Exchange Act of 1934 (Sections 10(b) and 20(a)) and SEC …
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Published: August 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. (UNCY)
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics (UNCY) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC has filed a shareholder class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Read More
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disease (CKD).
Read More
Investor Alert: Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Class Action
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Published: August 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
Published: July 19, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Read More
About Unicycive Therapeutics, Inc. (UNCY)
- IPO Date 2021-07-12
- Website https://www.unicycive.com
- Industry Biotechnology
- CEO Shalabh K. Gupta MPA
- Employees 22